Psoriasis

The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis provides an opportunity for clinicians to share knowledge and research.

Websites and educational materials are available to support clinicians in treating their patients with skin of color.

Expert dermatologists review a case of a 61-year-old female patient with GPP with no personal or family history of the condition.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, reviews the many pathways of generalized pustular psoriasis (GPP), focusing on individualizing therapy for patients with GPP and treatment options.

Lakshi Aldredge, MSN, ANP-BC, and Jennifer Conner, MPAS, PA-C, share treatment approaches to metabolic syndrome as a comorbidity with plaque psoriasis.

Experts in dermatological conditions review the case of a 40-year-old female with a long history of plaque psoriasis, highlighting the psychosocial impact of the disease and the importance of multidisciplinary care.

To further discuss the changing landscape of skin of color representation in dermatology, Christopher Bunick, MD, PhD, and Shawn Kwatra, MD, review how they have seen representation change in their own experiences.

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, define what differentiates generalized pustular psoriasis (GPP) from other forms of psoriasis and discuss tools for diagnosing GPP.

Erin Boh, MD, emphasizes the importance of patient empowerment and physician education surrounding the management of GPP.

Patients treated by rheumatologists were more often treated with tumor necrosis factor inhibitors.

Lakshi Aldredge, MSN, ANP-BC, comments on the role of nurse practitioners and physician assistants in plaque psoriasis treatment management. Jennifer Conner, MPAS, PA-C, reviews the long-term considerations with systemic therapy.

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Apremilast treatment for psoriasis and psoriatic arthritis can be managed effectively through telehealth visits.

In the cohort trial, 85% of patients showed an improvement of more than 50 on PASI.

Click here to answer this week’s poll.

Experts in dermatology hypothesize about the management of patients with chronic vs acute GPP episodes.

Erin Boh, MD, discusses the role of steroid administration and withdrawal as a trigger for GPP, highlighting the importance of physician awareness of external influences initiating this condition.

The findings highlight new data on AXL expression in inflammatory diseases.

Dermatology experts discuss the use of systemic therapy in plaque psoriasis and determining patient response to treatment, also commenting on the use of PASI scoring in the clinical setting.

Jennifer Conner, MPAS, PA-C, and Terry Faleye, MPAS, PA-C, review a case of a young adult female with plaque psoriasis on the elbows, thighs, and scalp, and discuss switching systemic treatments to accommodate her lifestyle.

As Psoriasis Awareness Month 2023 comes to a close, Dermatology Times is reviewing the top psoriasis headlines and news from August.

Patients with psoriasis treated with IL-23i and IL-17i had a decreased risk of developing pneumonia, otitis media, and upper respiratory tract infections.

Lauren Miller, MPAS, and T.J. Chao, MPAS, emphasized that clinicians need to be an advocate for patients and take that extra step to educate.

Researchers noted a lack of significant differences in access to biologics among different populations.

Alexandra Golant, MD, and Mona Shahriari, MD, shared pearls regarding the role of nonsteroidal topicals in the treatment of plaque psoriasis.

Experts in dermatology provide insight into the importance of multidisciplinary care in the management of patients with generalized pustular psoriasis (GPP).

Erin Boh, MD, shares her opinion on the importance of proactively stocking and streamlining generalized pustular psoriasis (GPP) medication pathways due to emergent care requirements of GPP.

Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.